Altered expression and endocytic function of CD205 in human dendritic cells, and detection of a CD205-DCL-1 fusion protein upon dendritic cell maturation

被引:57
作者
Butler, Matt
Morel, Anne-Sophie
Jordan, William J.
Eren, Efrem
Hue, Susan
Shrimpton, Rachel E.
Ritter, Mary A.
机构
[1] Univ London Imperial Coll Sci Technol & Med, Dept Immunol, Fac Med, London W12 0NN, England
[2] Univ Med & Dent New Jersey, Dept Oral Biol, Newark, NJ 07103 USA
关键词
dendritic cell; c-type lectin; expression; endocytosis;
D O I
10.1111/j.1365-2567.2006.02512.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
CD205 (DEC-205) is a member of the macrophage mannose receptor family of C-type lectins. These molecules are known to mediate a wide variety of biological functions including the capture and internalization of ligands for subsequent processing and presentation by dendritic cells. Although its ligands await identification, the endocytic properties of CD205 make it an ideal target for those wishing to design vaccines and targeted immunotherapies. We present a detailed analysis of CD205 expression, distribution and endocytosis in human monocyte-derived dendritic cells undergoing lipopolysaccharide-induced maturation. Unlike other members of the macrophage mannose receptor family, CD205 was up-regulated upon dendritic cell maturation. This increase was a result of de novo synthesis as well as a redistribution of molecules from endocytic compartments to the cell surface. Furthermore, the endocytic capacity of CD205 was abrogated and small amounts of the recently identified CD205-DCL-1 fusion protein were detected in mature DC. Our results suggest that CD205 has two distinct functions - one as an endocytic receptor on immature dendritic cells and a second as a non-endocytic molecule on mature dendritic cells - and further highlight its potential as an immuno-modulatory target for vaccine and immunotherapy development.
引用
收藏
页码:362 / 371
页数:10
相关论文
共 64 条
[1]   Targeting dendritic cells with antigen-containing liposomes: antitumour immunity [J].
Altin, JG ;
van Broekhoven, CL ;
Parish, CR .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (11) :1735-1747
[2]   Differential expression of gp200-MR6 molecule in benign hyperplasia and down-regulation in invasive carcinoma of the breast [J].
AlTubuly, AA ;
Luqmani, YA ;
Shousha, S ;
Melcher, D ;
Ritter, MA .
BRITISH JOURNAL OF CANCER, 1996, 74 (07) :1005-1011
[3]  
AlTubuly AA, 1997, INT J CANCER, V71, P605, DOI 10.1002/(SICI)1097-0215(19970516)71:4<605::AID-IJC16>3.0.CO
[4]  
2-A
[5]   DC-SIGN and LFA-1: a battle for ligand [J].
Bleijs, DA ;
Geijtenbeek, TBH ;
Figdor, CG ;
van Kooyk, Y .
TRENDS IN IMMUNOLOGY, 2001, 22 (08) :457-463
[6]   Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance [J].
Bonifaz, L ;
Bonnyay, D ;
Mahnke, K ;
Rivera, M ;
Nussenzweig, MC ;
Steinman, RM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (12) :1627-1638
[7]   In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination [J].
Bonifaz, LC ;
Bonnyay, DP ;
Charalambous, A ;
Darguste, DI ;
Fujii, SI ;
Soares, H ;
Brimnes, MK ;
Moltedo, B ;
Moran, TM ;
Steinman, RM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (06) :815-824
[8]   Origin, maturation and antigen presenting function of dendritic cells [J].
Cella, M ;
Sallusto, F ;
Lanzavecchia, A .
CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (01) :10-16
[9]   Dendritic cell (DC)-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin (DC-SIGN, CD209), a C-type surface lectin in human DCs, is a receptor for Leishmania amastigotes [J].
Colmenares, M ;
Puig-Kröger, A ;
Pello, OM ;
Corbí, AL ;
Rivas, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (39) :36766-36769
[10]  
DEMAAGD RA, 1985, IMMUNOLOGY, V54, P745